BioInvent International AB (OTCPK:BOVNF)
$ 4.7 0 (0%) Market Cap: 268.98 Mil Enterprise Value: 170.35 Mil PE Ratio: 0 PB Ratio: 2.59 GF Score: 59/100

Q3 2023 BioInvent International AB Earnings Call Transcript

Oct 26, 2023 / 12:00PM GMT
Release Date Price: $4.7
Martin Welschof
BioInvent International AB - CEO

Thank you very much, and welcome, everybody, to our call today. It's the interim report, January to September 2023. I am Martin Welschof, the CEO, and I will start the presentation. Later, the second part of the presentation will be covered by Stefan Ericsson, our CFO.

I would start with a quick summary of the interim report, so briefly go over the events in the third quarter. So we had the first patient recruited into our Phase A (sic - see Presentation, slide 2, "Phase 2a") trial of single-agent BI-1808 for the treatment of advanced malignancies. That was a very important milestone for the company, and I will come back to that later in a little bit more detail.

Then we also initiated the subcutaneous arm of our Phase 1/2 clinical trial for solid tumors for BI-1206 in combination with pembrolizumab.

Then on the collaboration side, as you probably will remember, we're quite active on that as well. So we have signed the agreement with Exelixis and actually achieved the first research milestone, which was triggering a USD1

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot